X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Procter & Gamble Health with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs DR. DATSONS LABS - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH DR. DATSONS LABS PROCTER & GAMBLE HEALTH/
DR. DATSONS LABS
 
P/E (TTM) x 48.9 -10.9 - View Chart
P/BV x 4.4 0.2 2,725.3% View Chart
Dividend Yield % 10.7 0.0 -  

Financials

 PROCTER & GAMBLE HEALTH   DR. DATSONS LABS
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
DR. DATSONS LABS
Mar-14
PROCTER & GAMBLE HEALTH/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs3,549126 2,825.6%   
Low Rs1,30131 4,211.3%   
Sales per share (Unadj.) Rs511.4133.0 384.6%  
Earnings per share (Unadj.) Rs61.30.2 40,425.3%  
Cash flow per share (Unadj.) Rs74.06.6 1,120.1%  
Dividends per share (Unadj.) Rs440.000-  
Dividend yield (eoy) %18.10-  
Book value per share (Unadj.) Rs927.8128.8 720.4%  
Shares outstanding (eoy) m16.6031.66 52.4%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x4.70.6 805.9%   
Avg P/E ratio x39.6516.1 7.7%  
P/CF ratio (eoy) x32.811.8 276.7%  
Price / Book Value ratio x2.60.6 430.2%  
Dividend payout %717.90-   
Avg Mkt Cap Rs m40,2572,477 1,625.0%   
No. of employees `0001.1NA-   
Total wages/salary Rs m1,31356 2,344.1%   
Avg. sales/employee Rs Th7,486.7NM-  
Avg. wages/employee Rs Th1,157.6NM-  
Avg. net profit/employee Rs Th897.2NM-  
INCOME DATA
Net Sales Rs m8,4904,211 201.6%  
Other income Rs m24479 309.9%   
Total revenues Rs m8,7344,289 203.6%   
Gross profit Rs m1,482569 260.6%  
Depreciation Rs m211204 103.3%   
Interest Rs m0430 0.0%   
Profit before tax Rs m1,51413 11,923.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5636 9,221.3%   
Profit after tax Rs m1,0175 21,195.8%  
Gross profit margin %17.513.5 129.2%  
Effective tax rate %37.148.0 77.3%   
Net profit margin %12.00.1 10,511.9%  
BALANCE SHEET DATA
Current assets Rs m15,3436,852 223.9%   
Current liabilities Rs m1,9606,711 29.2%   
Net working cap to sales %157.63.3 4,707.2%  
Current ratio x7.81.0 766.6%  
Inventory Days Days49161 30.3%  
Debtors Days Days28318 8.9%  
Net fixed assets Rs m1,2093,673 32.9%   
Share capital Rs m166317 52.4%   
"Free" reserves Rs m15,2353,761 405.1%   
Net worth Rs m15,4014,078 377.7%   
Long term debt Rs m01,671 0.0%   
Total assets Rs m17,59512,633 139.3%  
Interest coverage xNM1.0-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.50.3 144.8%   
Return on assets %5.83.4 167.9%  
Return on equity %6.60.1 5,611.7%  
Return on capital %10.37.7 133.7%  
Exports to sales %022.9 0.0%   
Imports to sales %014.3 0.0%   
Exports (fob) Rs mNA964 0.0%   
Imports (cif) Rs mNA602 0.0%   
Fx inflow Rs m1,636964 169.7%   
Fx outflow Rs m4,368607 719.5%   
Net fx Rs m-2,732357 -765.4%   
CASH FLOW
From Operations Rs m-1,3041,345 -97.0%  
From Investments Rs m12,697-2,256 -562.9%  
From Financial Activity Rs m-301-1,200 25.0%  
Net Cashflow Rs m11,093-2,111 -525.6%  

Share Holding

Indian Promoters % 0.0 4.5 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 0.0 -  
FIIs % 1.0 1.4 74.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 94.1 30.9%  
Shareholders   28,591 20,807 137.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   ALEMBIC LTD  SUN PHARMA  PFIZER  FDC LTD.  AUROBINDO PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks(The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Aug 23, 2019 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS